ESMO Congress | Conference

One Year of Adjuvant Trastuzumab Remains Standard of Care

October 3rd 2012

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

Bevacizumab Plus Chemotherapy Improves Response Rates and PFS in Platinum-Resistant Ovarian Cancer

October 2nd 2012

An exploratory analysis of the phase III AURELIA trial affirms the benefit of adding bevacizumab to chemotherapy for patients with platinum-resistant recurrent ovarian cancer.

No Survival Advantage for Ifosfamide Added to Doxorubicin in Advanced Soft Tissue Sarcoma

October 2nd 2012

The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.

Pazopanib Another Front-Line Therapy Option for Metastatic Renal Cell Carcinoma

October 2nd 2012

Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.

Updated Data Show T-DM1 Improves Overall Survival in HER2-Positive Breast Cancer

October 1st 2012

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Positive Results in ALK-Positive NSCLC With First ALK Inhibitor

October 1st 2012

Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.

Updated Regorafenib Survival Results Confirm Effectiveness

October 1st 2012

Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.

Dr. Ezra Cohen on the Pharmacokinetics of Cabozantinib

September 30th 2012

Ezra E.W. Cohen, MD, from the University of Chicago Medical Center, on the pharmacokinetics and efficacy of cabozantinib for medullary thyroid cancer.

Does Docetaxel Add Benefit to the Oral Fluoropyrimidine S-1 in Gastric Cancer?

September 30th 2012

Two analyses, two different conclusions in Asian START trial when docetaxel was added to S-1 for patients with previously untreated advanced or recurrent gastric cancer.

BRAF Inhibitor Plus MEK Inhibitor Encouraging in Metastatic Melanoma

September 29th 2012

Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.

Gefitinib: Small Benefit as Second-Line Therapy in Esophageal Cancer

September 29th 2012

Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.

Conference Coverage From the 2012 ESMO Congress

September 20th 2012

Coverage from the 2012 European Society for Medical Oncology congress, held at the Austria Center Vienna from September 28 - October 2, in Vienna, Austria.